ClinicalTrials.gg
CompletedNCT03230292Updated Jul 22, 2022Results posted

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

A Phase 2 interventional study of Bimekizumab in Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 10 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
16th of 20
43 · median 161
Started
2017
with 1 other
Phase 2
6 of 20
1 open now
Registered
5th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 16th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 2, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Chronic Plaque Psoriasis
  • Bimekizumab
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have completed all dosing requirements in PS0016 without meeting any withdrawal criteria
  • Female subjects must be , permanently sterilized or, if of , must be willing to use a highly effective method of up till 20 weeks after last administration of study drug, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose
  • Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication (anticipated 5 half-lives)

Exclusion criteria

Exclusion Criteria:

  • Subjects previously participating in this study
  • Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study. Note: For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including herpes zoster or hospitalizations) in PS0016, the Medical Monitor must be consulted prior to the subject's entry into PS0018
  • Subject has any current sign or symptom that may indicate a medically significant infection
  • Subject has current clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, tuberculosis (TB), nontuberculous mycobacteria (NTMB),Blastomyces, Aspergillus, or Candidiasis (systemic). Any subject diagnosed with Histoplasmosis, Coccidiodes, Paracoccidioides, Pneumocystis, TB, NTMB, Blastomyces, Aspergillus, or Candidiasis (systemic) during PS0016 is excluded from PS0018 even if treatment has been completed.
  • Any subject who meets any withdrawal criteria in the feeder study (PS0016) is excluded from participating in the open-label extension study (PS0018)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is \>=50% to \<75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.

    Drug: Bimekizumab

Interventions

  • Bimekizumab will be administered subcutaneously in 2 different doses.

    Also known as: UCB4940

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Event (TEAE) Adjusted by Duration of Participant Exposure to Treatment

    TEAEs were events that had a start date on or after the first administration of study treatment in PS0018 until the last received dose of investigational medicinal product (IMP) +140 days \[which covered the 20-week Safety Follow-Up (SFU) Visit\]. The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline (Week 0) until Safety Follow Up Visit (up to Week 64)

Secondary outcomes

  1. Plasma Concentration of Bimekizumab During the Study

    Plasma concentration of Bimekizumab was expressed in micrograms per milliliter (μg/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (=0.075 μg/mL) in calculations of Means and Coefficient of Variations (CVs). Means and CVs were only calculated if at least 2/3 of the concentrations were quantified at the respective timepoint.

    Time frame: From Baseline (Week 0) until Safety Follow Up Visit (up to Week 64)

  2. Percentage of Participants With Positive Anti-bimekizumab (BZK) Antibody Levels Prior to Study Treatment

    For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: Baseline of study PS0016 [NCT03025542]

  3. Percentage of Participants With Overall Positive Anti-bimekizumab (BZK) Antibody Levels Following Study Treatment

    For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  4. Percentage of Participants Achieving a 50% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study

    The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI50 responses were based on at least 50% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  5. Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study

    The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI75 responses were based on at least 75% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  6. Percentage of Participants Achieving a 90% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study

    The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI90 responses were based on at least 90% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  7. Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI) During the Study

    The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI100 responses were based on 100% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  8. Percentage of Participants With Investigator´s Global Assessment (IGA) Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0=Clear to 4=Severe. The response was defined as clear \[0\] or almost clear \[1\] with at least 2 category improvement from PS0016 Baseline. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  9. Mean Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study

    The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  10. Mean Percentage Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study

    A negative percentage change from PS0016 baseline indicated improvement in Total PASI score. The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last Observation Carried Forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  11. Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Clear IGA was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  12. Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  13. Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  14. Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  15. Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Severe was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  16. Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  17. Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  18. Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  19. Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Moderate was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  20. Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study

    A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  21. Mean Percentage in the Body Surface Area (BSA) Affected by Psoriasis During the Study

    The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last Observation Carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  22. Mean Percentage Change From PS0016 [NCT03025542] Baseline in the Body Surface Area (BSA) Affected by Psoriasis During the Study

    The percentage BSA (0 to 100%) affected by PSO was listed by PS0016 randomized treatment, by study participant and visit including the percentage change from PS0016 Baseline. The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018

  23. Mean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Score During the Study

    HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: Week 0, 12, 24, 36, and 48 of study PS0018, Relative to Baseline of study PS0016 [NCT03025542]

  24. Mean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Score During the Study

    HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: Week 0, 12, 24, 36, and 48 of study PS0018, Relative to Baseline of study PS0016 [NCT03025542]

  25. Percentage of Participants With Scores Below 8 in HADS-A (Participants With Normal Scores) During the Study

    HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: Baseline of study PS0016 [NCT03025542], Week 0, 12, 24, 36, and 48 of study PS0018

  26. Percentage of Participants With Scores Below 8 in HADS-D (Participants With Normal Scores) During the Study

    HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

    Time frame: Baseline of study PS0016 [NCT03025542], Week 0, 12, 24, 36, and 48 of study PS0018

07

Results

Posted Mar 31, 2022

Participant flow

The study started to enroll patients in July 2017 and concluded in March 2019.

Participant flow — Overall Study
MilestoneBKZ All Participants
Started43
Completed37
Not completed6
Withdrew: Adverse event1
Withdrew: Protocol violation1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Event (TEAE) Adjusted by Duration of Participant Exposure to Treatment

TEAEs were events that had a start date on or after the first administration of study treatment in PS0018 until the last received dose of investigational medicinal product (IMP) +140 days \[which covered the 20-week Safety Follow-Up (SFU) Visit\]. The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline (Week 0) until Safety Follow Up Visit (up to Week 64)
Reported as:
Number · no. of new events per 100 subject-years
Incidence of Treatment Emergent Adverse Event (TEAE) Adjusted by Duration of Participant Exposure to Treatment
no. of new events per 100 subject-yearsBKZ All Participants (SS)
Incidence of Treatment Emergent Adverse Event (TEAE) Adjusted by Duration of Participant Exposure to Treatment76.00 (53.8 to 104.3)
SecondaryPlasma Concentration of Bimekizumab During the Study

Plasma concentration of Bimekizumab was expressed in micrograms per milliliter (μg/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (=0.075 μg/mL) in calculations of Means and Coefficient of Variations (CVs). Means and CVs were only calculated if at least 2/3 of the concentrations were quantified at the respective timepoint.

Time frame:
From Baseline (Week 0) until Safety Follow Up Visit (up to Week 64)
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab During the Study
μg/mLBKZ All Participants (PK-PPS)
PS0018 Week 0NA ± NA
Week 45.309 ± 47.8
Week 87.304 ± 60.7
Week 127.994 ± 53.9
Week 168.700 ± 53.7
Week 289.285 ± 49.7
Week 409.238 ± 51.3
Week 48/ Withdrawal9.056 ± 52.5
Follow-up0.310 ± 164.8
SecondaryPercentage of Participants With Positive Anti-bimekizumab (BZK) Antibody Levels Prior to Study Treatment

For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
Baseline of study PS0016 [NCT03025542]
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-bimekizumab (BZK) Antibody Levels Prior to Study Treatment
percentage of participantsBKZ All Participants (SS)
Percentage of Participants With Positive Anti-bimekizumab (BZK) Antibody Levels Prior to Study Treatment2.3
SecondaryPercentage of Participants With Overall Positive Anti-bimekizumab (BZK) Antibody Levels Following Study Treatment

For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Positive Anti-bimekizumab (BZK) Antibody Levels Following Study Treatment
percentage of participantsBKZ All Participants (SS)
Percentage of Participants With Overall Positive Anti-bimekizumab (BZK) Antibody Levels Following Study Treatment25.6
SecondaryPercentage of Participants Achieving a 50% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study

The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI50 responses were based on at least 50% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 50% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 060.5 (45.6 to 73.6)
Week 495.3 (84.5 to 98.7)
Week 895.3 (84.5 to 98.7)
Week 1295.3 (84.5 to 98.7)
Week 1697.7 (87.9 to 99.6)
Week 2095.3 (84.5 to 98.7)
Week 2493.0 (81.4 to 97.6)
Week 2893.0 (81.4 to 97.6)
Week 3290.7 (78.4 to 96.3)
Week 3690.7 (78.4 to 96.3)
Week 4088.4 (75.5 to 94.9)
Week 4490.7 (78.4 to 96.3)
Week 48/ Withdrawal88.4 (75.5 to 94.9)
Follow-Up79.1 (64.8 to 88.6)
SecondaryPercentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study

The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI75 responses were based on at least 75% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 044.2 (30.4 to 58.9)
Week 488.4 (75.5 to 94.9)
Week 895.3 (84.5 to 98.7)
Week 1290.7 (78.4 to 96.3)
Week 1693.0 (81.4 to 97.6)
Week 2090.7 (78.4 to 96.3)
Week 2490.7 (78.4 to 96.3)
Week 2888.4 (75.5 to 94.9)
Week 3290.7 (78.4 to 96.3)
Week 3690.7 (78.4 to 96.3)
Week 4086.0 (72.7 to 93.4)
Week 4490.7 (78.4 to 96.3)
Week 48/ Withdrawal86.0 (72.7 to 93.4)
Follow-Up65.1 (50.2 to 77.6)
SecondaryPercentage of Participants Achieving a 90% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study

The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI90 responses were based on at least 90% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 90% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 020.9 (11.4 to 35.2)
Week 453.5 (38.9 to 67.5)
Week 879.1 (64.8 to 88.6)
Week 1279.1 (64.8 to 88.6)
Week 1686.0 (72.7 to 93.4)
Week 2079.1 (64.8 to 88.6)
Week 2479.1 (64.8 to 88.6)
Week 2881.4 (67.4 to 90.3)
Week 3281.4 (67.4 to 90.3)
Week 3686.0 (72.7 to 93.4)
Week 4076.7 (62.3 to 86.8)
Week 4486.0 (72.7 to 93.4)
Week 48/ Withdrawal79.1 (64.8 to 88.6)
Follow-Up58.1 (43.3 to 71.6)
SecondaryPercentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI) During the Study

The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI100 responses were based on 100% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI) During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 04.7 (1.3 to 15.5)
Week 423.3 (13.2 to 37.7)
Week 837.2 (24.4 to 52.1)
Week 1246.5 (32.5 to 61.1)
Week 1639.5 (26.4 to 54.4)
Week 2048.8 (34.6 to 63.2)
Week 2441.9 (28.4 to 56.7)
Week 2846.5 (32.5 to 61.1)
Week 3241.9 (28.4 to 56.7)
Week 3641.9 (28.4 to 56.7)
Week 4046.5 (32.5 to 61.1)
Week 4446.5 (32.5 to 61.1)
Week 48/ Withdrawal46.5 (32.5 to 61.1)
Follow-Up18.6 (9.7 to 32.6)
SecondaryPercentage of Participants With Investigator´s Global Assessment (IGA) Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0=Clear to 4=Severe. The response was defined as clear \[0\] or almost clear \[1\] with at least 2 category improvement from PS0016 Baseline. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator´s Global Assessment (IGA) Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 018.6 (9.7 to 32.6)
Week 462.8 (47.9 to 75.6)
Week 879.1 (64.8 to 88.6)
Week 1279.1 (64.8 to 88.6)
Week 1681.4 (67.4 to 90.3)
Week 2079.1 (64.8 to 88.6)
Week 2476.7 (62.3 to 86.8)
Week 2879.1 (64.8 to 88.6)
Week 3286.0 (72.7 to 93.4)
Week 3681.4 (67.4 to 90.3)
Week 4079.1 (64.8 to 88.6)
Week 4483.7 (70.0 to 91.9)
Week 48/ Withdrawal79.1 (64.8 to 88.6)
Follow-Up51.2 (36.8 to 65.4)
SecondaryMean Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study

The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Mean · score on a scale
Mean Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study
score on a scaleBKZ All Participants (FAS)
PS0018 Week 0-11.21 ± 9.13
Week 4-16.79 ± 6.72
Week 8-18.12 ± 7.41
Week 12-18.70 ± 7.89
Week 16-19.01 ± 8.70
Week 20-18.91 ± 8.70
Week 24-19.08 ± 8.66
Week 28-19.13 ± 8.79
Week 32-19.30 ± 8.66
Week 36-19.27 ± 8.68
Week 40-19.22 ± 8.82
Week 44-19.32 ± 8.68
Week 48/ Withdrawal-19.20 ± 8.76
Follow-up-15.93 ± 9.29
SecondaryMean Percentage Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study

A negative percentage change from PS0016 baseline indicated improvement in Total PASI score. The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last Observation Carried Forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Mean · percentage change
Mean Percentage Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study
percentage changeBKZ All Participants (FAS)
PS0018 Week 0-56.45 ± 38.26
Week 4-87.71 ± 15.52
Week 8-93.28 ± 12.13
Week 12-94.50 ± 8.22
Week 16-95.15 ± 8.43
Week 20-94.84 ± 9.02
Week 24-95.69 ± 6.77
Week 28-95.72 ± 7.35
Week 32-96.85 ± 4.81
Week 36-96.66 ± 4.88
Week 40-96.13 ± 6.38
Week 44-96.98 ± 4.14
Week 48/ Withdrawal-96.10 ± 7.45
Follow-Up-81.98 ± 25.45
SecondaryPercentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Clear IGA was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 04.7
Week 423.3
Week 837.2
Week 1244.2
Week 1634.9
Week 2041.9
Week 2437.2
Week 2839.5
Week 3237.2
Week 3637.2
Week 4037.2
Week 4437.2
Week 48/ Withdrawal39.5
Follow-Up18.6
SecondaryPercentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 011.6
Week 437.2
Week 832.6
Week 1223.3
Week 1637.2
Week 2023.3
Week 2430.2
Week 2830.2
Week 3237.2
Week 3630.2
Week 4027.9
Week 4432.6
Week 48/ Withdrawal25.6
Follow-Up30.2
SecondaryPercentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 025.6
Week 418.6
Week 814.0
Week 1211.6
Week 169.3
Week 2014.0
Week 249.3
Week 287.0
Week 322.3
Week 369.3
Week 409.3
Week 442.3
Week 48/ Withdrawal7.0
Follow-Up11.6
SecondaryPercentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 025.6
Week 44.7
Week 80
Week 122.3
Week 162.3
Week 202.3
Week 242.3
Week 282.3
Week 320
Week 360
Week 402.3
Week 444.7
Week 48/ Withdrawal4.7
Follow-Up11.6
SecondaryPercentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Severe was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 016.3
Week 40
Week 80
Week 120
Week 160
Week 200
Week 240
Week 280
Week 320
Week 360
Week 400
Week 440
Week 48/ Withdrawal0
Follow-Up4.7
SecondaryPercentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 00
Week 40
Week 80
Week 122.3
Week 164.7
Week 207.0
Week 244.7
Week 287.0
Week 324.7
Week 367.0
Week 4011.6
Week 449.3
Week 48/ Withdrawal9.3
Follow-Up0
SecondaryPercentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 02.3
Week 42.3
Week 89.3
Week 129.3
Week 164.7
Week 207.0
Week 244.7
Week 282.3
Week 327.0
Week 367.0
Week 402.3
Week 444.7
Week 48/ Withdrawal4.7
Follow-Up2.3
SecondaryPercentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 02.3
Week 49.3
Week 82.3
Week 120
Week 164.7
Week 200
Week 244.7
Week 284.7
Week 322.3
Week 360
Week 400
Week 440
Week 48/ Withdrawal0
Follow-Up7.0
SecondaryPercentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Moderate was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 02.3
Week 42.3
Week 80
Week 122.3
Week 160
Week 200
Week 240
Week 280
Week 320
Week 360
Week 400
Week 440
Week 48/ Withdrawal0
Follow-Up2.3
SecondaryPercentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study

A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study
percentage of participantsBKZ All Participants (FAS)
PS0018 Week 09.3
Week 42.3
Week 82.3
Week 120
Week 160
Week 200
Week 240
Week 280
Week 320
Week 360
Week 400
Week 440
Week 48/ Withdrawal0
Follow-Up2.3
SecondaryMean Percentage in the Body Surface Area (BSA) Affected by Psoriasis During the Study

The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last Observation Carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Mean · percentage of BSA
Mean Percentage in the Body Surface Area (BSA) Affected by Psoriasis During the Study
percentage of BSABKZ All Participants (FAS)
PS0016 Baseline25.8 ± 17.5
PS0018 Week 08.6 ± 10.7
Week 45.2 ± 12.6
Week 83.0 ± 10.9
Week 122.0 ± 4.8
Week 161.0 ± 1.6
Week 201.2 ± 2.2
Week 241.2 ± 1.9
Week 280.9 ± 1.6
Week 320.8 ± 1.1
Week 360.7 ± 1.1
Week 400.8 ± 1.2
Week 440.7 ± 1.0
Week 48/ Withdrawal0.7 ± 1.2
Follow-Up4.8 ± 13.0
SecondaryMean Percentage Change From PS0016 [NCT03025542] Baseline in the Body Surface Area (BSA) Affected by Psoriasis During the Study

The percentage BSA (0 to 100%) affected by PSO was listed by PS0016 randomized treatment, by study participant and visit including the percentage change from PS0016 Baseline. The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Reported as:
Mean · percentage change
Mean Percentage Change From PS0016 [NCT03025542] Baseline in the Body Surface Area (BSA) Affected by Psoriasis During the Study
percentage changeBKZ All Participants (FAS)
PS0018 Week 0-61.0 ± 41.5
Week 4-83.0 ± 23.7
Week 8-91.1 ± 15.9
Week 12-92.9 ± 10.9
Week 16-95.5 ± 7.4
Week 20-94.4 ± 9.1
Week 24-94.8 ± 7.8
Week 28-95.4 ± 8.7
Week 32-96.1 ± 6.7
Week 36-96.5 ± 5.7
Week 40-95.8 ± 8.5
Week 44-96.3 ± 6.2
Week 48/ Withdrawal-95.6 ± 10.0
Follow-Up-81.5 ± 33.9
SecondaryMean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Score During the Study

HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
Week 0, 12, 24, 36, and 48 of study PS0018, Relative to Baseline of study PS0016 [NCT03025542]
Reported as:
Mean · score on a scale
Mean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Score During the Study
score on a scaleBKZ All Participants (FAS)
PS0018 Week 0-1.5 ± 2.3
Week 12-2.0 ± 1.8
Week 24-2.0 ± 2.4
Week 36-2.0 ± 2.4
Week 48/ Withdrawal-1.5 ± 2.2
SecondaryMean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Score During the Study

HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
Week 0, 12, 24, 36, and 48 of study PS0018, Relative to Baseline of study PS0016 [NCT03025542]
Reported as:
Mean · score on a scale
Mean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Score During the Study
score on a scaleBKZ All Participants (FAS)
PS0018 Week 0-1.0 ± 1.4
Week 12-0.8 ± 2.1
Week 24-1.0 ± 1.7
Week 36-1.1 ± 1.7
Week 48/ Withdrawal-1.0 ± 1.8
SecondaryPercentage of Participants With Scores Below 8 in HADS-A (Participants With Normal Scores) During the Study

HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
Baseline of study PS0016 [NCT03025542], Week 0, 12, 24, 36, and 48 of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants With Scores Below 8 in HADS-A (Participants With Normal Scores) During the Study
percentage of participantsBKZ All Participants (FAS)
PS0016 Baseline83.7
PS0018 Week 088.4
Week 1295.2
Week 2490.5
Week 3689.7
Week 48/ Withdrawal87.2
SecondaryPercentage of Participants With Scores Below 8 in HADS-D (Participants With Normal Scores) During the Study

HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.

Time frame:
Baseline of study PS0016 [NCT03025542], Week 0, 12, 24, 36, and 48 of study PS0018
Reported as:
Number · percentage of participants
Percentage of Participants With Scores Below 8 in HADS-D (Participants With Normal Scores) During the Study
percentage of participantsBKZ All Participants (FAS)
PS0016 Baseline93.0
PS0018 Week 097.7
Week 1295.2
Week 2497.6
Week 3694.9
Week 48/ Withdrawal97.4

Adverse events

Collected over Adverse events were collected from the PS0018 Baseline until the Safety Follow-Up Visit [20 weeks after the last dose (up to Week 64)]. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BKZ All Participants (SS)0/43 (0%)3/43 (7%)27/43 (62.8%)
Most frequent serious events
Most frequent serious events
EventBKZ All Participants (SS)
Acute myocardial infarctionCardiac disorders1/43
Anaemia postoperativeInjury, poisoning and procedural complications1/43
SyncopeNervous system disorders1/43
Most frequent other events
Most frequent other events
EventBKZ All Participants (SS)
Upper respiratory tract infectionInfections and infestations8/43
NasopharyngitisInfections and infestations7/43
Viral upper respiratory tract infectionInfections and infestations5/43
Gamma-glutamyltransferase increasedInvestigations5/43
Oral candidiasisInfections and infestations4/43
Alanine aminotransferase increasedInvestigations4/43
PharyngitisInfections and infestations3/43
Staphylococcal pharyngitisInfections and infestations3/43

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all study participants who received at least 1 dose of investigational medicinal product (IMP) in PS0018.

Age, Categorical
Age, Categorical(Participants)BKZ All Participants
<=18 years0
Between 18 and 65 years40
>=65 years3
Age, Continuous
Age, Continuous(years)BKZ All Participants
Mean45.0 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)BKZ All Participants
Female20
Male23
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BKZ All Participants
Asian4
Black or African American1
Native Hawaiian or Other Pacific Islander1
White37
08

Study locations

10 sites
  • Ps0018 701
    High Point, North Carolina 27265, United States
  • Ps0018 704
    Bexley, Ohio 43209, United States
  • Ps0018 101
    Carlton, Australia
  • Ps0018 103
    East Melbourne, Australia
  • Ps0018 102
    Kogarah, Australia
  • Ps0018 104
    Woolloongabba, Australia
  • Ps0018 201
    Ajax, Canada
  • Ps0018 203
    London, Canada
  • Ps0018 202
    Windsor, Canada
  • Ps0018 501
    Chisinau, Moldova, Republic of
09

References and documents

Publications

  • Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PubMed 35544084 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Mar 2019, 20 months.

Results were first posted in Mar 2022, 3 years after primary completion. A results delay was requested in Mar 2020.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 20 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2017
First posted
Jul 26, 2017
StartActual
Jul 3, 2017
Primary completionActual
Mar 6, 2019
CompletionActual
Mar 6, 2019
Results delay requested
Mar 5, 2020
Results first posted
Mar 31, 2022
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03230292
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jul 26, 2017
Start date
Jul 3, 2017
Primary completion
Mar 6, 2019
Completion
Mar 6, 2019
Results posted
Mar 31, 2022
Last update
Jul 22, 2022

Study contacts

UCB Cares
study director · UCB (001 844 599 2273)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion